Lercanidipine Hcl Amarox (Lercanidipine)

Lercanidipine is a calcium channel blocker used to manage hypertension, a condition characterized by elevated arterial pressure.

• Hypertension: lowers both systolic and diastolic blood pressure, helping to achieve target levels in adult patients.
• Essential hypertension: provides sustained vasodilation, contributing to long‑term control of primary high blood pressure.
• Isolated systolic hypertension: reduces elevated systolic pressure, particularly in older adults where pulse pressure is high.
• High cardiovascular risk patients: when combined with other antihypertensives, it assists in overall risk management.

• Lercanidipine selectively inhibits L-type calcium channels in vascular smooth muscle cells, preventing calcium influx that is necessary for contraction. This results in arterial vasodilation, reduced peripheral resistance, and consequently a decrease in systemic blood pressure without significant effect on cardiac conduction.

Lercanidipine may cause a range of adverse reactions. Most are mild and reversible, but rare serious events can occur.

Common Side Effects

• Headache: mild to moderate intensity, often transient.
• Flushing: sensation of warmth and redness, usually temporary.
• Peripheral edema: swelling of ankles or lower limbs due to fluid accumulation.
• Dizziness: light‑headed feeling, especially after standing.

Serious or Rare Side Effects

• Severe hypotension: marked drop in blood pressure requiring medical attention.
• Angioedema: swelling of face, lips, tongue or throat that may compromise airway.
• Liver injury: abnormal liver enzymes or hepatitis, necessitating monitoring.

Before initiating therapy, clinicians should consider several safety aspects.

• Blood pressure monitoring: check baseline and periodic readings before and during therapy.
• Cardiovascular status: avoid in patients with unstable angina or recent myocardial infarction.
• Liver function: assess hepatic impairment before initiating.
• Elderly patients: start at lower dose and monitor for edema.
• Drug interactions: review concomitant medications that affect CYP3A4.
• Store at ambient temperature: keep below 25°C in the original container, protect from moisture.

Lercanidipine can interact with several medicines, altering its effectiveness or safety.

Major Interactions (Avoid)

• CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase plasma levels.
• Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce efficacy.
• Grapefruit juice: can raise drug concentration.

Moderate Interactions (Monitor Closely)

• Beta‑blockers: additive blood pressure lowering effect.
• Diuretics: may enhance antihypertensive effect, monitor electrolytes.
• ACE inhibitors/ARBs: combined therapy may increase risk of hypotension.